Role of androgens in normal and pathological ovarian function
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Androgens mediate their actions via the androgen receptor (AR), a member of the nuclear receptor superfamily. AR-mediated androgen action is essential in male reproductive development and function; however, only in the last decade has the suspected but unproven role for AR-mediated actions in female reproduction been firmly established. Deciphering the specific roles and precise pathways by which AR-mediated actions regulate ovarian function has been hindered by confusion on how to interpret results from pharmacological studies using androgens that can be converted into oestrogens, which exert actions via the oestrogen receptors. The generation and analysis of global and cell-specific female Ar knockout mouse models have deduced a role for AR-mediated actions in regulating ovarian function, maintaining female fertility, and have begun to unravel the mechanisms by which AR-mediated androgen actions regulate follicle health, development and ovulation. Furthermore, observational findings from human studies and animal models provide substantial evidence to support a role for AR-mediated effects not only in normal ovarian function but also in the development of the frequent ovarian pathological disorder, polycystic ovarian syndrome (PCOS). This review focuses on combining the findings from observational studies in humans, pharmacological studies and animal models to reveal the roles of AR-mediated actions in normal and pathological ovarian function. Together these findings will enable us to begin understanding the important roles of AR actions in the regulation of female fertility and ovarian ageing, as well as providing insights into the role of AR actions in the androgen-associated reproductive disorder PCOS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group (2004) · Human Reproduction · doi:10.1093/humrep/deh098 · Cited by 6,138
Franks, S. (1995) · New England Journal of Medicine · doi:10.1056/nejm199509283331307 · Cited by 2,463
The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders
Miller, W. L., & Auchus, R. J. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0013 · Cited by 2,458 · cited 1×
“…itself can then be aromatised into oestradiol (E2) by P450arom (CYP19) or reduced to DHT by 5a-reductase 1 (SRD5A1) and 2 (SRD5A2), the latter of which can be enzymatically reduced into 5aandrostanediols, reversibly into 3a-diol and irreversibly into 3b-diol (Longcope 1986, Miller & Auchus 2011).”
BackgroundAzziz, R., Carmina, E., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Futterweit, W., Janssen, O. E., Legro, R. S., Norman, R. J., Taylor, A. E., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0178 · Cited by 2,143 · cited 1×
“This definition for PCOS was followed in 2006 by the Androgen Excess PCOS Society’s recommended diagnostic criteria of the presence of hyperandrogenism, and/or oligo-ovulation and polycystic ovaries, and the exclusion of other related disorders (Azziz et al. 2006, 2009).”
MethodAzziz, R., Carmina, E., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Futterweit, W., Janssen, O. E., Legro, R. S., Norman, R. J., Taylor, A. E., et al. (2009) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.06.035 · Cited by 2,132 · cited 1×
“This definition for PCOS was followed in 2006 by the Androgen Excess PCOS Society’s recommended diagnostic criteria of the presence of hyperandrogenism, and/or oligo-ovulation and polycystic ovaries, and the exclusion of other related disorders (Azziz et al. 2006, 2009).”
MethodFauser, B. C. J. M., Tarlatzis, B. C., Rebar, R. W., Legro, R. S., Balen, A. H., Lobo, R., Carmina, E., Chang, J., Yildiz, B. O., Laven, J. S. E., et al. (2012) · Fertility and Sterility · doi:10.1016/j.fertnstert.2011.09.024 · Cited by 1,976 · cited 1×
“It is characterised by reproductive, endocrine and metabolic features including anovulation, infertility, hyperandrogenism, obesity, hyperinsulinism and an increased risk of type 2 diabetes and cardiovascular disease (Fauser et al. 2012).”
BackgroundPolycystic ovary syndrome: etiology, pathogenesis and diagnosis
Goodarzi, M. O., Dumesic, D. A., Chazenbalk, G., & Azziz, R. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.217 · Cited by 1,488 · cited 1×
“…ovary syndrome (PCOS), a common condition causing anovulation and infertility, and associated with an increase in metabolic abnormalities including obesity, insulin resistance, dyslipidaemia, cardiovascular disease and type 2 diabetes (Franks 1995, Pasquali et al. 2010, Goodarzi et al. 2011).”
BackgroundOvarian aging: mechanisms and clinical consequences
Broekmans, F. J., Soules, M. R., & Fauser, B. C. (2009) · Endocrine Reviews · doi:10.1210/er.2009-0006 · Cited by 1,248 · cited 1×
“Ovarian reserve declines steeply with age, and older women undergoing IVF yield fewer oocytes even after maximal FSH stimulation (Broekmans et al. 2009).”
BackgroundAndrogen Levels in Adult Females: Changes with Age, Menopause, and Oophorectomy
Davison, S. L., Bell, R., Donath, S., Montalto, J. G., & Davis, S. R. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0212 · Cited by 998 · cited 1×
“Population studies demonstrate a decrease in circulating blood levels of testosterone, DHEA and A4 concentrations in women gradually between the ages of 20 and 45 years of age, without specific effects of the menopausal transition (Zumoff et al. 1995, Davison et al. 2005).”
BackgroundBurger, H. G. (2002) · Fertility and Sterility · doi:10.1016/s0015-0282(02)02985-0 · Cited by 771 · cited 2×
“However, only testosterone and DHT (a pure, non-aromatisable androgen three to ten times more potent than testosterone) bind directly to the AR, while the others are androgen precursors that require conversion to testosterone and/or DHT to exert androgenic effects (Burger 2002).”
BackgroundAndrogens stimulate early stages of follicular growth in the primate ovary
Vendola, K. A., Zhou, J., Adesanya, O. O., Weil, S. J., & Bondy, C. A. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2081 · Cited by 712 · cited 7×
“…are significantly increased in primate ovaries after treatment with either an aromatisable (testosterone) or a non-aromatisable androgen (DHT) (Vendola et al. 1998), and follicle atresia is significantly decreased with follicles exhibiting fewer apoptotic granulosa cells (Vendola et al. 1998).”
BackgroundInfluentialThe polycystic ovary syndrome: a position statement from the European Society of Endocrinology
Conway, G., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Franks, S., Gambineri, A., Kelestimur, F., Macut, D., Micic, D., Pasquali, R., et al. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0253 · Cited by 676
Androgen and follicle stimulating hormone interactions in primate ovarian follicle development
Weil, S., Vendola, K., Zhou, J., & Bondy, C. A. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.8.5929 · Cited by 592
Follicle dynamics and anovulation in polycystic ovary syndrome
Franks, S., Stark, J., & Hardy, K. (2008) · Human Reproduction Update · doi:10.1093/humupd/dmn015 · Cited by 581
Nelson, V. L., Legro, R. S., Strauss, J. F., & McAllister, J. M. (1999) · Molecular Endocrinology · doi:10.1210/mend.13.6.0311 · Cited by 556
Abbott, D. H., Barnett, D. K., Bruns, C. M., & Dumesic, D. A. (2005) · Human Reproduction Update · doi:10.1093/humupd/dmi013 · Cited by 555 · cited 6×
“…2012a, Sen & Hammes 2010, Wu et al. 2014) and PCOS models in rodents (Walters et al. 2012b), sheep (Padmanabhan & Veiga-Lopez 2013) and primates (Abbott et al. 2005) induced by excess androgen exposure provides unique mechanistic insights into the role for AR-mediated androgen actions in…”
BackgroundInfluentialNon-genomic actions of androgens
Foradori, C. D., Weiser, M. J., & Handa, R. J. (2008) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2007.10.005 · Cited by 493 · cited 1×
“…androgens are also reportedly capable of non-genomic AR actions, where androgenic actions occur within seconds or minutes after ligand binding, too quickly for nuclear translocation, and the androgenic response is insensitive to inhibitors of transcription or translocation (Foradori et al. 2008).”
BackgroundOvarian and adrenal contribution to peripheral androgens during the menstrual cycle
ABRAHAM, G. E. (1974) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-39-2-340 · Cited by 436
Zumoff, B., Strain, G. W., Miller, L. K., & Rosner, W. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.4.7714119 · Cited by 392 · cited 1×
“Population studies demonstrate a decrease in circulating blood levels of testosterone, DHEA and A4 concentrations in women gradually between the ages of 20 and 45 years of age, without specific effects of the menopausal transition (Zumoff et al. 1995, Davison et al. 2005).”
BackgroundWeil, S. J., Vendola, K., Zhou, J., Adesanya, O. O., Wang, J., Okafor, J., & Bondy, C. A. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.7.4917 · Cited by 359 · cited 3×
“During the follicular and luteal phases, stroma within primate ovaries exhibits AR protein (Hild-Petito et al. 1991) and mRNA (Weil et al. 1998), and human ovarian stromal cells also express AR protein (Suzuki et al. 1994).”
BackgroundVendola, K., Zhou, J., Wang, J., Famuyiwa, O. A., Bievre, M., & Bondy, C. A. (1999) · Biology of Reproduction · doi:10.1095/biolreprod61.2.353 · Cited by 324
Barnes, R. B., Rosenfield, R. L., Ehrmann, D. A., Cara, J. F., Cuttler, L., Levitsky, L. L., & Rosenthal, I. M. (1994) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.79.5.7962325 · Cited by 304 · cited 1×
“Observations supporting this hypothesis include the findings that women with foetal androgen excess disorders such as congenital 21-hydroxylase deficiency and congenital adrenal virilising tumours develop PCOS features during their adult life (Hague et al. 1990, Barnes et al. 1994).”
BackgroundPrenatal androgen exposure programs metabolic dysfunction in female mice
Roland, A. V., Nunemaker, C. S., Keller, S. R., & Moenter, S. M. (2010) · Journal of Endocrinology · doi:10.1677/joe-10-0217 · Cited by 184
Walters, K. A., Simanainen, U., & Handelsman, D. J. (2010) · Human Reproduction Update · doi:10.1093/humupd/dmq003 · Cited by 183 · cited 1×
“Various clinical observational studies and in vitro pharmacological studies have provided evidence to support the direct involvement of AR-mediated actions in female reproduction (reviewed in Walters et al. (2008, 2010)).”
BackgroundSelf-citationAbbott, D. H., Tarantal, A. F., & Dumesic, D. A. (2009) · American Journal of Primatology · doi:10.1002/ajp.20679 · Cited by 177 · cited 1×
“…also present in female monkeys exposed to TP during early–mid-gestation, including increased abdominal adiposity, hyperlipidaemia, hyperglycaemia, impaired pancreatic b-cell function, insulin resistance and type 2 diabetes (Eisner et al. 2003, Abbott et al. 2005, 2009, 2013, Keller et al. 2014).”
BackgroundFoecking, E. M., Szabo, M., Schwartz, N. B., & Levine, J. E. (2005) · Biology of Reproduction · doi:10.1095/biolreprod.105.039800 · Cited by 165
Xu, N., Kwon, S., Abbott, D. H., Geller, D. H., Dumesic, D. A., Azziz, R., Guo, X., & Goodarzi, M. O. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027286 · Cited by 155 · cited 1×
“…in a prenatally androgenised primate PCOS model, implying that an increased predisposition to PCOS may be induced by www.reproduction-online.org Downloaded from Bioscientifica.com at 12/04/2022 10:09:07PM via free access excess foetal androgen exposure altering the epigenome (Xu et al. 2011).”
BackgroundNotini, A. J., Davey, R. A., McManus, J. F., Bate, K. L., & Zajac, J. D. (2005) · Journal of Molecular Endocrinology · doi:10.1677/jme.1.01884 · Cited by 145 · cited 2×
“…ARKO mice cannot be generated by natural breeding owing to obligate paternal sterility of hemizygous males bearing an inactive AR (the classical complete androgen insensitivity syndrome (CAIS), formerly known as testicular feminisation syndrome (tfm)) (Goldstein & Wilson 1972, Notini et al. 2005).”
BackgroundBosdou, J. K., Venetis, C. A., Kolibianakis, E. M., Toulis, K. A., Goulis, D. G., Zepiridis, L., & Tarlatzis, B. C. (2012) · Human Reproduction Update · doi:10.1093/humupd/dmr051 · Cited by 141 · cited 1×
“A meta-analysis confirmed that transdermal testosterone treatment increased pregnancy and live-birth rates, but there were insufficient data to support a beneficial role for DHEA or letrozole (Bosdou et al. 2012).”
BackgroundIncreased Adiposity in Female Rhesus Monkeys Exposed to Androgen Excess During Early Gestation
Eisner, J. R., Dumesic, D. A., Kemnitz, J. W., Colman, R. J., & Abbott, D. H. (2003) · Obesity Research · doi:10.1038/oby.2003.42 · Cited by 133 · cited 1×
“…also present in female monkeys exposed to TP during early–mid-gestation, including increased abdominal adiposity, hyperlipidaemia, hyperglycaemia, impaired pancreatic b-cell function, insulin resistance and type 2 diabetes (Eisner et al. 2003, Abbott et al. 2005, 2009, 2013, Keller et al. 2014).”
BackgroundPalomba, S., Falbo, A., Chiossi, G., Muscogiuri, G., Fornaciari, E., Orio, F., Tolino, A., Colao, A., La Sala, G. B., & Zullo, F. (2014) · Steroids · doi:10.1016/j.steroids.2014.06.005 · Cited by 69
Keller, E., Chazenbalk, G. D., Aguilera, P., Madrigal, V., Grogan, T., Elashoff, D., Dumesic, D. A., & Abbott, D. H. (2014) · Endocrinology · doi:10.1210/en.2014-1050 · Cited by 60 · cited 1×
“…also present in female monkeys exposed to TP during early–mid-gestation, including increased abdominal adiposity, hyperlipidaemia, hyperglycaemia, impaired pancreatic b-cell function, insulin resistance and type 2 diabetes (Eisner et al. 2003, Abbott et al. 2005, 2009, 2013, Keller et al. 2014).”
BackgroundPrenatally injected testosterone propionate and sexual behavior of female rats
Huffman, L., & Hendricks, S. E. (1981) · Physiology & Behavior · doi:10.1016/0031-9384(81)90097-4 · Cited by 33 · cited 1×
“…late gestational treatment of mice with testosterone (Keisler et al. 1991) or rats with TP (Swanson & Werff ten Bosch 1964, 1965, Fels & Bosch 1971, Huffman & Hendricks 1981, Slob et al. 1983, Tyndall et al. 2012) had no effect on cyclicity or ovarian function, inferred by the presence of…”
Background
Cited by
Ovulation: Parallels With Inflammatory Processes
Duffy, D. M., Ko, C., Jo, M., Brannstrom, M., & Curry, T. E. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00075 · Cited by 513
New Perspectives on the Pathogenesis of PCOS: Neuroendocrine Origins
Walters, K. A., Gilchrist, R. B., Ledger, W. L., Teede, H. J., Handelsman, D. J., & Campbell, R. E. (2018) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2018.08.005 · Cited by 186
Self-citationThe interplay between androgens and the immune response in polycystic ovary syndrome
Shabbir, S., Khurram, E., Moorthi, V. S., Eissa, Y. T. H., Kamal, M. A., & Butler, A. E. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04116-4 · Cited by 108
Androgens and ovarian function: translation from basic discovery research to clinical impact
Walters, K. A., Rodriguez Paris, V, Aflatounian, A., & Handelsman, D. J. (2019) · Journal of Endocrinology · doi:10.1530/joe-19-0096 · Cited by 104
“2012a, 2018a, Walters 2015).”
Self-citationXiao, S., Li, Y., Long, L., Luo, C., & Mai, Q. (2016) · Gynecological Endocrinology · doi:10.3109/09513590.2015.1076784 · Cited by 15
Metadata
- Authors
- Walters, K. A.
- Venue
- Reproduction
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-04-01
- Volume
- 149
- Issue
- 4
- Pages
- R193-R218
- ISSN
- 1470-1626 (ISSN-L)
- 1741-7899
- OpenAlex
- W2015522428
- Cited by
- 166
- References
- 33
- FWCI
- 14.37
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.